Withdrawal Notice
This paper was originally published in Oncotarget Advance Online Publications on 12/21/2017.In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.
Research Papers:
Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of surviving promoter-driven HSVtk in hepatocellular carcinoma
Fanxiu Meng1*, Lina Zhang1*, Chunyang Xu2, Qi Zhang1, Yongfang Li1, Yingmin Zhang1, Na Zhao1, Baofeng Yu1, Rui Guo1, Hailong Wang1, Jun Xie1, Gongqin Sun1,3, Gaopeng Li4, Jun Xu4, Qin Qin5 and Xiushan Dong6
1 Department of Biochemistry and Molecular Biology, Basic Medical Science, Shanxi Medical University, Taiyuan, Shanxi, China
2 Department of Biological Sciences, The Dietrich School of Arts & Sciences, University Of Pittsburgh, Pittsburgh, PA 15260, USA
3 Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, USA.
4 Department of General Surgery, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
5 Central Laboratory, Shanxi Provincial People’s Hospital, Shanxi Medical University, Taiyuan, Shanxi, China
6 Department of General Surgery, Shanxi Dayi Hospital, Taiyuan, Shanxi, China
* These authors have contributed equally to this work
Correspondence to:
Baofeng Yu, email: [email protected]
Jun Xu, email: [email protected]
Keywords: hepatocellular carcinoma; gene therapy; HSVtk/GCV; GP73; apoptosis
Received: July 29, 2017 Accepted: October 28, 2017 Epub: December 21, 2017
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23565